Frank Blank

Doctoral Dissertation Announcement

---

Candidate: James McGee

Degree of: Doctor of Philosophy

Department: Biological Sciences

Title: Identification, Development, and Screening of Compounds against Bacterial Glutamate Racemase

Committee:
Dr. Bruce Bejcek, Chair
Dr. Alexander Enyedi
Dr. John Spitsbergen
Dr. John Geiser
Dr. Sitta Sittapalam

Date: Friday, August 31, 2012 2:00 p.m. to 4:00 p.m.
1710 Wood Hall

Abstract:
The first potent inhibitors of glutamate racemase (MurI) enzyme that show whole cell antibacterial activity are described. Optically pure 4-substituted D-glutamic acid analogues with (2R,4S) stereochemistry and bearing aryl-, heteroaryl-, cinnamyl-, or biaryl-methyl substituents represent a novel class of glutamate racemase inhibitors. Exploration of the D-Glu core led to the identification of lead compounds (-)-8 and 10. 2-Naphthylmethyl derivative 10 was found to be a potent competitive inhibitor of glutamate racemase activity (Ki ) 16 nM, circular dichroism assay; IC50 ) 0.1 μg/mL high-performance liquid chromatography (HPLC) assay). Thorough structure-activity relationship (SAR) studies led to benzothienyl derivatives such as 69 and 74 with increased potency (IC50 ) 0.036 and 0.01 μg/mL, respectively, HPLC assay). These compounds showed potent whole cell antibacterial activity against S. pneumoniae PN-R6, and good correlation with the enzyme assay. Compounds 69, 74 and biaryl derivative 52 showed efficacy in an in vivo murine thigh infection model against Streptococcus pneumoniae. Data described herein suggest that glutamate racemase may be a viable target for developing new antibacterial agents.